01640nas a2200529   4500000000100000000000100001000000100002008004100003653002400044653001900068653005700087653005600144653006900200653002800269653004600297653001200343653001100355653005300366653001100419653006100430653003200491653003200523653002000555653003800575653004600613653004700659653005700706100001600763700001500779700002000794700001400814700001600828700001400844700001400858700001000872700002300882700001200905700001600917700001100933700001300944700001400957245009500971250001501066300000801081490000701089020001401096       2022                            d10aCanada/epidemiology10aCohort Studies10a*Diabetes Mellitus, Type 2/drug therapy/epidemiology10a*Dipeptidyl-Peptidase IV Inhibitors/therapeutic use10aDipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use10aGlucagon-Like Peptide 110aGlucagon-Like Peptide-1 Receptor/agonists10aGlucose10aHumans10aHypoglycemic Agents/pharmacology/therapeutic use10aSodium10a*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use10a*Symporters/therapeutic use10aUnited Kingdom/epidemiology10aType 2 diabetes10adipeptidyl peptidase 4 inhibitors10aglucagon-like peptide 1 receptor agonists10asodium-glucose co-transporter 2 inhibitors10anot involving SGLT-2 inhibitors or DPP-4 inhibitors.1 aV. Brunetti1 aA. St-Jean1 aS. Dell'Aniello1 aA. Fisher1 aO. H. Y. Yu1 aS. Bugden1 aJ. Daigle1 aN. Hu1 aS. Alessi-Severini1 aB. Shah1 aP. Ronksley1 aL. Lix1 aP. Ernst1 aK. Filion00aCharacteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom  a2022/09/30  a2410 v22  a1472-6823